Association of skeletal muscle mass with safety and efficacy of atezolizumab (atezo) plus bevacizumab (bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the ELIXIR study

被引：0

作者：

Hiraoka, A. ^{[1
]}

Aikata, H. ^{[2
]}

Moriguchi, M. ^{[3
]}

Ikeda, M. ^{[4
]}

Morimoto, N. ^{[5
]}

Tsuchiya, K. ^{[6
]}

Takehara, T. ^{[7
]}

Nagai, H. ^{[8
]}

Sakamori, R. ^{[9
]}

Nakamura, S. ^{[10
]}

Tsuji, K. ^{[11
,12
]}

Kuroda, H. ^{[13
]}

Shimizu, M. ^{[14
]}

Shiina, S. ^{[15
]}

Yamasaki, T. ^{[16
]}

Kudo, M. ^{[17
]}

Kokudo, N. ^{[18
]}

Furuse, J. ^{[19
]}

Yamamoto, K. ^{[20
]}

Yamashita, T. ^{[21
]}

机构：

[1] Ehime Prefectural Cent Hosp, Gastroenterol, Matsuyama, Ehime, Japan

[2] Hiroshima Prefectural Hosp, Gastroenterol, Minami, Japan

[3] Kyoto Prefectural Univ Med, Mol Gastroenterol & Hepatol, Kyoto, Japan

[4] Natl Canc Ctr Hosp East, Hepatobiliary & Pancreat Oncol Dept, Kashiwa, Chiba, Japan

[5] Jichi Med Univ Hosp, Dept Gastroenterol, Shimotsuke, Tochigi, Japan

[6] Japanese Red Cross Musashino Hosp, Dept Gastroenterol & Hepatol, Musashino, Tokyo, Japan

[7] Osaka Univ, Gastroenterol & Hepatol, Suita, Osaka, Japan

[8] Toho Univ, Div Gastroenterol & Hepatol, Med Ctr, Omori Hosp, Ota Ku, Ota, Japan

[9] Natl Hosp Org Osaka Natl Hosp, Gastroenterol & Hepatol, Osaka, Japan

[10] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Hyogo, Japan

[11] Hiroshima Red Cross Hosp, Gastroenterol, Hiroshima, Japan

[12] Atom Bomb Survivors Hosp, Hiroshima, Japan

[13] Iwate Med Univ, Dept Internal Med, Div Gastroenterol & Hepatol, Morioka, Iwate, Japan

[14] Gifu Univ, Gastroenterol, Grad Sch Med, Gifu, Japan

[15] Juntendo Univ, Dept Gastroenterol, Grad Sch Med, Bunkyo Ku, Tokyo, Japan

[16] Yamaguchi Univ, Dept Oncol & Lab Med, Grad Sch Med, Ube, Yamaguchi, Japan

[17] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[18] NCGM Natl Ctr Global Hlth & Med, Surg, Shinjuku Ku, Tokyo, Japan

[19] Kanagawa Canc Ctr, Dept Gastroenterol, Yokohama, Kanagawa, Japan

[20] Yokohama City Univ Med, Dept Biostat, Yokohama, Kanagawa, Japan

[21] Kanazawa Univ, Dept Gastroenterol, Kanazawa, Ishikawa, Japan

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.1015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

955P

引用

页码：S660 / S661

页数：2

共 50 条

[1] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Kuzuya, T.
Yamashita, T.
Takehara, T.
Aikata, H.
Kato, N.
Hiasa, Y.
Nakamura, S.
Morimoto, N.
Moriguchi, M.
Ikeda, M.
Inoue, J.
Tani, J.
Ueno, Y.
Chayama, K.
Tateishi, R.
Kawamura, Y.
Furuse, J.
Kudo, M.
Yamamoto, K.
Kokudo, N.
ANNALS OF ONCOLOGY, 2023, 34 : S1531 - S1532
[2] Safety and efficacy of atezolizumab (Atezo) plus bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): A prospective, multicenter, observational study (ELIXIR) - A preliminary analysis
Ikeda, M.
Kato, N.
Kagawa, T.
Yamashita, T.
Moriguchi, M.
Nakamura, S.
Sawada, K.
Iijima, H.
Kamoshida, T.
Nakao, K.
Ohkawa, K.
Sugimoto, R.
Takehara, T.
Harada, M.
Yamamoto, Y.
Ito, T.
Kudo, M.
Kokudo, N.
Yamamoto, K.
Furuse, J.
ANNALS OF ONCOLOGY, 2022, 33 : S1467 - S1467
[3] Randomised efficacy and safety results for atezolizumab (Atezo) plus bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Hsu, C-H.
Lee, M. S.
Lee, K-H.
Numata, K.
Stein, S.
Verret, W.
Hack, S.
Spahn, J.
Liu, B.
Huang, C.
He, R.
Ryoo, B-Y.
ANNALS OF ONCOLOGY, 2019, 30
[4] Randomised efficacy and safety results for atezolizumab (Atezo) plus bevacizumab (Bev) in patients (pts) with previously untreated, unresectable hepatocellular carcinoma (HCC)
Lee, M.
Ryoo, B-Y.
Hsu, C-H.
Numata, K.
Stein, S.
Verret, W.
Hack, S.
Spahn, J.
Liu, B.
Abdullah, H.
He, R.
Lee, K-H.
ANNALS OF ONCOLOGY, 2019, 30 : 875 - 875
[5] Disease etiology and efficacy outcomes with atezolizumab plus bevacizumab (atezo-bev) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Multinational retrospective analysis
Kim, S.
Lee, S. Y.
Park, Y. G.
Kim, H-D.
Lee, J. J. X.
Ryu, M. H.
Ryoo, B-Y.
Tai, D. W. M.
Yoo, C.
ANNALS OF ONCOLOGY, 2023, 34 : S609 - S610
[6] Final analysis of the ELIXIR study: A prospective, multicenter, observational study to evaluate the efficacy and safety of atezolizumab plus bevacizumab (Atezo plus Bev) in Japanese patients with unresectable hepatocellular carcinoma (uHCC) in a real-world clinical setting
Takehara, T.
Kato, N.
Aikata, H.
Kuzuya, T.
Hiasa, Y.
Nakamura, S.
Yamamoto, K.
Morimoto, N.
Sakamori, R.
Kawamura, Y.
Tsuchiya, K.
Ueshima, K.
Hiraoka, A.
Nakano, M.
Kokudo, N.
Furuse, J.
Moriguchi, M.
Yamashita, T.
Ikeda, M.
Kudo, M.
ANNALS OF ONCOLOGY, 2024, 35 : S1480 - S1481
[7] Retrospective study of the correlation between proteinuria and renal function in patients (pts) with unresectable hepatocellular carcinoma (uHCC) treated with atezolizumab plus bevacizumab (Atezo plus Bev): ARISE study
Ueshima, K.
Nishida, N.
Hagihara, S.
Minami, Y.
Ida, H.
Takita, M.
Chishina, H.
Morita, M.
Aoki, T.
Kudo, M.
ANNALS OF ONCOLOGY, 2023, 34 : S1542 - S1542
[8] Efficacy of atezolizumab (atezo) plus bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)
He, A. R. R.
Numata, K.
Lee, K-H.
Hsu, C-H.
Lee, J.
Morimoto, M.
Verret, W.
Hack, S. P.
Spahn, J.
Liu, B.
Ryoo, B-Y.
ANNALS OF ONCOLOGY, 2020, 31 : S690 - S690
[9] Atezolizumab (ATEZO) plus Bevacizumab ( BEV) vs Sorafenib (SOR) in Patients (PTS) with Unresectable Hepatocellular Carcinoma (HCC): Phase 3 Results from Imbrave150
Galle, Peter R.
Cheng, Ann-Lll
Qin, Shukui
Ikeda, Masafumi
Ducreux, Michel
Zhu, Andrew
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed
Li, Daneng
Verret, Wendy
Xu, Derek
Hernandez, Sairy
Liu, Juan
Shao, Hui
Mulla, Sohail
Lim, Hy
Finn, Richard
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 220 - 220
[10] The comparative efficacy of atezolizumab and bevacizumab versus lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC).
Trueman, David
Liu, Yifeng
Lucero, Melanie
Meier, Genevieve
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →